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Abstract
Background: Francisella tularensis is a Gram-negative coccobacillus that causes the febrile illness tularemia. Subspecies that
are pathogenic for humans include those comprising the type A (subspecies tularensis) or type B (subspecies holarctica)
biovars. An attenuated live vaccine strain (LVS) developed from a type B isolate has previously been used to vaccinate at-risk
individuals, but offers limited protection against high dose (.1000 CFUs) challenge with type A strains delivered by the
respiratory route. Due to differences between type A and type B F. tularensis strains at the genetic level, it has been
speculated that utilization of an attenuated type A strain as a live vaccine might offer better protection against homologous
respiratory challenge compared with LVS. Here, we report the construction and characterization of an unmarked DpurMCD
mutant in the highly virulent type A strain Schu S4.
Methodology/Principal Findings: Growth of Schu S4 DpurMCD was severely attenuated in primary human peripheral blood
monocyte-derived macrophages and in the A549 human lung epithelial cell line. The Schu S4 DpurMCD mutant was also
highly attenuated in mice when delivered via either the intranasal or intradermal infection route. Mice vaccinated
intranasally with Schu S4 DpurMCD were well protected against high dose intradermal challenge with virulent type A or
type B strains of F. tularensis. However, intranasal vaccination with Schu S4 DpurMCD induced tissue damage in the lungs,
and conferred only limited protection against high dose Schu S4 challenge delivered by the same route. The level of
protection observed was similar to that conferred following vaccination with wild-type LVS or the analogous LVS DpurMCD
mutant.
Conclusions/Significance: Collectively, these results argue that development of the next generation live attenuated vaccine
for Francisella should be based on use of the less pathogenic type B biovar rather than the more reactogenic type A biovar.
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Introduction
Francisella tularensis is one of the most infectious bacterial species
known, and is the etiological agent of the debilitating febrile illness
tularemia. F. tularensis is comprised of four subspecies, of which
subspecies tularensis (type A) and subspecies holarctica (type B) are
the biovars most commonly associated with disease in humans.
Type A strains cause the most severe disease manifestations, and
are primarily found in North America. F. tularensis can be
transmitted to humans from multiple reservoirs and via various
infection routes [1]. Pneumonic tularemia resulting from the
inhalation of aerosolized organisms is the most severe disease
form, and has mortality rates approaching 30% to 60% when
untreated [2,3]. Due to its extreme virulence, ease of dissemina-
tion, low infectious dose, and previous weaponization, F. tularensis
is considered a potential agent of bioterrorism. Currently, there is
no licensed vaccine in the event of an intentional or accidental
release of F. tularensis.
Attempts to develop a vaccine capable of inducing protective
immunity against type A strains of F. tularensis have met with
limited success. Early vaccine studies employed heat- or formalin-
killed whole cell vaccines that offered limited efficacy with adverse
side effects [4,5]. A number of potential antigens have been
identified and tested as components of subunit vaccines, but none
aside from lipopolysaccharide have shown appreciable protective
efficacy [6,7]. A live vaccine strain (LVS) was developed in the
former Soviet Union from multiple passages of the less pathogenic
type B biovar, and remains the only available vaccine shown to
offer significant protection against virulent F. tularensis strains.
LVS, however, remains unlicensed in the United States as a
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many animals including mice. Early experiments involving human
volunteers demonstrated that LVS given by scarification conferred
protection against subsequent systemic type A challenge [3,8].
LVS also protected against low-dose aerosol challenge (10–100
CFUs) with type A F. tularensis; however, it was unable to protect
against a high dose aerosol challenge, the most likely dispersion
route during a biological attack [2,8]. Human studies involving
respiratory vaccination with high doses of 10
6–10
8 LVS have
demonstrated that this route of immunization enhances protective
immunity against a large Schu S4 aerosol challenge (roughly 2500
CFUs) over that seen with LVS vaccination by scarification [9,10].
Unfortunately, LVS was found to be more virulent to humans when
given via aerosol, and in some cases the dose needed for protection
resulted in tularemia, causing safety concerns for this delivery route
[10]. Regardless, the ability of LVS to confer protection in humans
demonstrates the potential for using live attenuated Francisella strains
as vaccine candidates against tularemia.
Due to differences in genetic makeup and disease pathology
between type A and type B F. tularensis, it has been predicted that
respiratory vaccination with an attenuated type A strain of F.
tularensis may offer the best protection against homologous
aerogenic challenge [6,7,11,12]. Until recently, construction of
targeted mutations in this genetic background has been limited
due to a lack of genetic tools and/or selectable markers. Recent
advances have allowed a small number of targeted mutants to be
generated and characterized in Schu S4, the prototypical type A F.
tularensis strain [12–15]. These include a Schu S4 mutant deleted
in the O-antigen locus wbtDEF. Although it is attenuated for growth
inmacrophagesandinmice,thisstrainfailstoprotectmicefollowing
subcutaneous vaccination against moderate doses of wild-type
SchuS4 delivered by the intraperitoneal route [14]. Similarly,
deletion of either iglC or FTT0918 attenuates growth of Schu S4 in
macrophages and/or in mice [12]. However, intradermal vaccina-
tion with the Schu S4 DiglC mutant does not provide appreciable
protective immunity, and the Schu S4 DFTT0918 mutant retains a
low level of virulence in mice following its administration by the
intradermal route [12]. Finally, although a Schu S4 dsbB deletion
mutant was found to be highly attenuated in mice following
intranasal infection, intranasal vaccination with this strain failed to
offer protection against challenge with even low doses (13 CFUs) of
wild-type Schu S4 given by the same infection route [13]. Thus,
none of the Schu S4 mutants generated to date have been found to
confer protective immunity against high dose challenge with virulent
type A strains of F. tularensis.
We recently reported that a marked deletion in an operon
essentialforpurine biosynthesis(purMCD)i nF.tularensisLVSresulted
in a strain that was highly attenuated for virulence in murine
macrophages and inmicewhendelivered bytheintraperitoneal(i.p.)
route of infection [16]. Furthermore, i.p. vaccination with this strain
was capable of conferring protective immunity in mice following
homologous challenge with wild-type LVS delivered by the same
route [16]. In this study, an unmarked DpurMCD mutant was
generated intype A strain Schu S4and its ability to confer protective
immunity against wild-type F. tularensis was investigated. Growth of
Schu S4 DpurMCD was highly attenuated in primary human
macrophages and in the human type II pneumocyte epithelial cell
line A549. Schu S4 DpurMCD was also highly attenuated in mice
when delivered by the intranasal or intradermal routes of infection.
However, intranasal vaccination of mice with the attenuated Schu
S4 DpurMCD mutant induced tissue damage in the lungs, and
resultedinaprotectiveimmuneresponsethatwasnobetterthanthat
seen following vaccination with wild-type LVS or an analogous LVS
DpurMCD mutant. Given these results, we argue that the next
generation Francisella vaccine should be based on the less pathogenic
type B biovar.
Results
Construction and complementation of unmarked
purMCD deletion mutants in F. tularensis LVS and Schu S4
The DpurMCD mutation previously generated in LVS carried a
kanamycin resistance marker for selection [16]. To alleviate
concerns associated with the use of antibiotic resistance genes in
type A F. tularensis, deletion of purMCD was performed in both LVS
and Schu S4 without the incorporation of an antibiotic resistance
marker. Potential unmarked purMCD mutants were screened for
auxotrophy on Chamberlain’s defined medium, and genetic
deletions were confirmed by PCR and Southern blot hybridization
(data not shown). There were no obvious growth defects of the
mutant strains on complex media when compared to the wild-type
parental strains (data not shown). Complementation of the
purMCD mutation was carried out in both strains by introduction
of the Francisella-Escherichia coli shuttle vector pFNLTP6 [17]
harboring the wild-type purMCDN operon. Introduction of this
plasmid completely restored growth of both LVS DpurMCD and
Schu S4 DpurMCD mutants on Chamberlain’s defined medium,
confirming that the auxotrophic phenotype was due to loss of
purMCD (data not shown).
Growth of Schu S4 DpurMCD is attenuated in human
macrophages and lung epithelial cells
Macrophages are a primary target for F. tularensis during
mammalian infection and are generally thought to contain limiting
concentrations of purines [18,19]. Previous characterization of the
LVS purMCD::Km
r mutant indicated that this strain was able to
infect murine macrophages and escape the host cell phagosome
prior to lysosomal fusion, but was unable to persist within the host
cell cytosol and was cleared shortly thereafter [16]. Schu S4
DpurMCD demonstrated a similar attenuation in both murine
peritoneal-derived primary macrophages and the macrophage-like
cell line J774A.1 (data not shown). To determine whether the
unmarked Schu S4 DpurMCD mutant was also attenuated for
growth in human cells, human peripheral blood monocyte-derived
macrophages (hMDM) were infected with this derivative at a
multiplicity of infection (MOI) of 1, and bacterial burden
determined every 16 hours for two days. Schu S4 DpurMCD was
significantly attenuated (P,0.01) in hMDMs relative to the wild-
type parent over the time course examined (Fig. 1A). Comple-
mentation with wild-type purMCDN in trans restored this growth
defect. In addition to macrophages, F. tularensis has also been
shown to associate with human alveolar type II lung epithelial cells
[20]. Therefore, growth of mutant F. tularensis derivatives was also
assessed in the A549 cell line. Growth of Schu S4 DpurMCD was
significantly attenuated relative to the wild-type and complement-
ed strains in these cells (P,0.05) (Fig. 1C). Similar results were also
observed in unmarked DpurMCD mutant and complemented
derivatives of LVS that were generated in parallel (Fig. 1B and D).
Thus, the inability of type A or type B F. tularensis to synthesize
purines de novo results in a severe growth defect in primary human
macrophages and cultured human lung epithelial cells.
Schu S4 DpurMCD is attenuated for virulence in mice
Previous studies of the LVS DpurMCD::Km
r mutant indicated
that this strain was highly attenuated for virulence in mice when
delivered via the i.p. infection route [16]. To determine whether
the unmarked DpurMCD mutants were attenuated in vivo when
delivered via more relevant routes of infection, groups (n=5) of
DpurMCD Mutants of Schu S4
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or intradermally (i.d.) with 10-fold serial dilutions (ranging from 10
CFUs to 10
6 CFUs) of wild-type, DpurMCD, or genetically
complemented Schu S4 or LVS mutant derivatives. Even at the
lowest dose tested, all mice succumbed to infection with either
wild-type Schu S4 or the complemented Schu S4 DpurMCD
mutant with mean times-to-death (MTD) of between 6–12 days.
Thus, the observed LD50 for these strains is ,10 CFUs (Table 1).
The higher MTD observed in the complemented Schu S4
DpurMCD mutant compared to wild-type Schu S4 is most likely
a consequence of plasmid instability or loss due to the inability to
maintain selection in vivo. In contrast, all animals infected either
i.n. or i.d. with Schu S4 DpurMCD displayed no overt disease
symptoms, and all animals survived infection for the 21-day
duration of the experiment (Table 1). Therefore, the LD50 of the
Schu S4 DpurMCD mutant is .10
6 CFUs. A similar pattern of
results was also observed in mice infected via either infection route
with the analogous LVS DpurMCD mutant and complemented
derivatives (data not shown). Thus, deletion of purMCD in type A
F. tularensis or in LVS results in severe virulence attenuation in the
intradermal and intranasal murine infection models.
Schu S4 DpurMCD is cleared in mice shortly after
infection
To determine whether Schu S4 DpurMCD persisted in target
organs after infection, groups (n=3) of age-matched mice were
infected i.n. or i.d. with either 50 CFUs of wild-type Schu S4, or
10
4 or 10
6 CFUs of Schu S4 DpurMCD and bacterial burdens
monitored in the lung, spleen, and liver over a 21 day period. Mice
inoculated with wild-type Schu S4 showed a rapid increase in
CFUs in target organs regardless of the route of infection, and all
animals died by 6 days post-infection (Fig. 2). In contrast, Schu S4
DpurMCD failed to replicate to high numbers in target organs, and
was eventually cleared. However, mutant organisms were
detectable for at least ten days post-infection (Fig. 2). Burdens
were highest in the lung following i.n. infection (Fig. 2A), with low
levels of organisms detected in the liver and spleen at the various
time points examined (Fig. 2B and C). Following i.d. infection,
Figure 1. Growth of F. tularensis derivatives in mammalian cells. Intracellular growth of F. tularensis Schu S4 and LVS derivatives in human
monocyte-derived macrophages (A and B), and A549 lung epithelial cells (C and D). Cells were infected with wild type F. tularensis LVS or Schu S4, LVS
or Schu S4 DpurMCD, or the LVS or Schu S4 genetically complemented DpurMCD, and intracellular growth was monitored by lysing cells at the
indicated time points and determining CFU by standard plate count. Infections were conducted at an MOI of 1, and gentamicin (5 mg/ml) was added
to culture medium after infection to kill extracellular organisms. Standard errors of organ burden from three individual mice are shown. Asterisks
indicate significance between wild-type or complemented DpurMCD mutants and DpurMCD burdens (P,0.05; two-way ANOVA).
doi:10.1371/journal.pone.0002487.g001
Table 1. Virulence of Schu S4 derivatives in BALB/c mice.
Strain Route Survival
a LD50
a,b MTD (days)
a
Schu S4 i.n. 0/5 ,10 6.6
i.d. 0/5 ,10 7.6
Schu S4 DpurMCD i.n. 5/5 .10
6 .21
i.d. 5/5 .10
6 .21
Schu S4 DpurMCD:pTZ752 i.n. 0/5 ,10 6.8
i.d. 0/5 ,10 11.6
aSurvival, LD50, and mean time-to-death (MTD) were determined 21 days after
infection for the lowest Schu S4 and Schu S4 DpurMCD:pTZ752 doses (10 CFU)
given, and the highest Schu S4 DpurMCD dose (10
6 CFU).
bLD50 values were calculated as described by Reed and Muench.
doi:10.1371/journal.pone.0002487.t001
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(Fig. 2F), but failed to disseminate to or survive in the lung and
liver even in animals receiving the highest dose (Fig. 2D and E).
Thus, Schu S4 DpurMCD persists in host tissues for up to 10 days
following infection, and its pattern and level of persistence is
dependent upon the route of infection and the relative dose
delivered.
Vaccination with Schu S4 DpurMCD increases the survival
probability in mice challenged intranasally with wild-type
Schu S4
To determine whether vaccination with Schu S4 DpurMCD
provided protective immunity against subsequent i.n. challenge
with wild-type type A F. tularensis, groups of age-matched mice
(n=5) were left unvaccinated or were vaccinated i.d. or i.n. with
increasing doses of Schu S4 DpurMCD. Mice were then challenged
21 days later i.n. with a moderate dose (500 CFUs) of Schu S4. All
naı ¨ve mice infected i.d. or i.n. with wild-type Schu S4 succumbed
to infection and exhibited a MTD of 5.8 days (Fig. 3A and B).
Both i.d. (Fig. 3A) and i.n. (Fig. 3B) vaccination with Schu S4
DpurMCD increased the overall survival of infected mice over the
naı ¨ve controls based on a trend test for survival probabilities
(P,0.0001) [21]. I.d. vaccination of mice with increasing doses of
Schu S4 DpurMCD enhanced the MTD from 5.8 days to 8.4 days,
while the MTD in mice vaccinated i.n. with escalating doses of the
mutant increased from 5.8 days to 11.4 days. Log-rank analysis
confirmed that both routes of vaccination significantly increased the
MTD over the naı ¨ve controls. Although all mice vaccinated i.d. with
Schu S4 DpurMCD eventually succumbed to infection following
challenge with Schu S4 (Fig. 3A), several mice vaccinated i.n. with
higher doses of Schu S4 DpurMCD survived this challenge (Fig. 3B).
Takentogether,theseresultsdemonstratethatvaccinationwithSchu
S4 DpurMCD enhances protection against respiratory challenge with
type A F. tularensis, with the greatest protection seen following
vaccination by the intranasal route.
Intranasal vaccination with Schu S4 DpurMCD protects
mice at levels that are comparable to that seen with LVS
or a LVS DpurMCD mutant
To date, mice vaccinated with attenuated type A F. tularensis
mutants have failed to confer protective immunity that is better
than that seen with LVS [12,13]. To gauge the extent of
protection conferred by Schu S4 DpurMCD, i.n. vaccination-
challenge studies were conducted in parallel with wild-type LVS
and an LVS DpurMCD mutant. Groups (n=3) of age-matched
mice were vaccinated i.n. with 10
2 CFUs of wild-type LVS, 10
6
CFUs of LVS DpurMCD,o r1 0
4 CFUs of Schu S4 DpurMCD,o r
were inoculated with PBS (sham control). A vaccination dose of
10
4 CFUs of Schu S4 DpurMCD was chosen based on the results
presented in Figure 3. Animals were then challenged 42 days post-
vaccination with moderate (1–1.5610
2 CFUs) or high (2–3610
3
CFUs) doses of virulent type A (Schu S4) or type B (NR-648) F.
tularensis via either the i.n. or i.d. route. In addition, half of the
vaccinated animals were boosted with the respective strain 21 days
post-vaccination to assess the affect of multiple immunizations on
protective immunity. Boosting doses included 2610
3 CFUs of
LVS, 1610
6 CFUs of Schu S4 DpurMCD,o r1 610
6 CFUs of LVS
DpurMCD. No CFUs were detected in the lung, spleen, or liver of
any of the vaccinated mice immediately prior to challenge (data
not shown). Naı ¨ve mice succumbed to infection with Schu S4 or
NR-648 within 5–7 days regardless of the challenge route or dose
(Table 2, rows 25–28). In contrast, mice vaccinated with a single
dose of the Schu S4 DpurMCD mutant were well protected against
both moderate and high dose i.d. challenge with Schu S4 or NR-
648 (Table 2, rows 17–20). However, protection from a single dose
Schu S4 DpurMCD vaccination was not notably better than in
naı ¨ve animals when challenge strains were delivered via the i.n.
route (Table 2, rows 17–20). Administration of a boost 21 days
post-vaccination increased the protective efficacy of Schu S4
DpurMCD, but these animals still remained susceptible to high dose
i.n. challenge with Schu S4 (Table 2, rows 21–24). Mice
vaccinated with a single dose of LVS were well protected against
i.d. infection with both moderate and high doses of Schu S4 and
NR-648 (Table 2, rows 1–4), and against moderate doses of Schu
S4 when administered via the i.n. route (Table 2, rows 1–4).
Inclusion of a booster LVS immunization provided only a minimal
increase in protection against high dose Schu S4 or NR-648 i.n.
challenge (Table 2, rows 5–8). Finally, mice vaccinated with a
single dose of LVS DpurMCD were as susceptible to i.d. or i.n.
Schu S4 and NR-648 challenge as unvaccinated controls (Table 2,
rows 9–12). However, protection was increased to levels
comparable to that seen with Schu S4 DpurMCD and wild-type
LVS following administration of a booster immunization (Table 2,
rows 13–16). For all strains tested, statistical analysis of data
revealed a clear trend of increasing survival probability upon
Figure 2. Growth characteristics of Schu S4 derivatives in
BALB/c mice. Groups of mice were infected i.n. (A, B, and C) or i.d. (D,
E, and F) with wild-type Schu S4 (50 CFU), or one of two doses of Schu
S4 DpurMCD (10
4 or 10
6 CFU). At specific times after infection, subsets
of mice were sacrificed and the numbers of bacteria present in the
lungs (A and D), livers (B and E), or spleens (C and F) were determined
by plating organ homogenates on MH agar containing ampicillin
(50 mg/ml). Values represent the mean log CFU per ml from groups of
three animals each. The horizontal dashed line represents the
confidence level of detection for the assay. Standard errors of organ
burdens for three individual mice are shown. Crosses indicate time
points where n=1; n=3 for all other time points.
doi:10.1371/journal.pone.0002487.g002
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addition, administration of a boosting dose at 21 days post-
vaccination collectively enhanced survival probability (P,0.0001).
Though able to offer significant protection in most scenarios, none
of the vaccine strains tested offered substantial protection against
high i.n. doses of Schu S4. Thus, after boosting, all strains tested
exhibited similar vaccine efficacy when comparing vaccinated to
naı ¨ve mice.
I.n. vaccination with Schu S4 DpurMCD fails to limit
growth of wild-type Schu S4 in the lungs of infected mice
To determine whether i.n. vaccination with Schu S4 DpurMCD
limited growth of wild-type Schu S4 in the lung, bacterial burdens
were determined in the lung, spleen, and liver of mice (n=3) at
one, three, and five days following i.n. challenge with 100 CFUs of
Schu S4. Mice vaccinated and boosted with Schu S4 DpurMCD
contained significantly reduced bacterial burdens in their liver
(P,0.01) and spleen (P,0.01) by 5 days post-challenge (Fig. 4A
and B). In contrast, no significant reduction in bacterial burden
was observed in the lungs of Schu S4 DpurMCD-vaccinated and
boosted mice at this time over the unvaccinated controls (Fig. 4C).
Mice receiving a single vaccination with Schu S4 DpurMCD did
not exhibit a significant reduction in bacterial burden in the lung,
spleen, or liver following Schu S4 challenge. These results indicate
that mice vaccinated i.n. with Schu S4 DpurMCD are less able to
limit Schu S4 proliferation in the lungs compared with the liver
and spleen following i.n. challenge.
Intranasal vaccination with Schu S4 DpurMCD induces
regions of acute inflammation in lung tissue
The ability to limit growth of the challenge strain in the spleen
and liver but not in the lungs following i.n. vaccination with Schu
S4DpurMCD suggested that the lung may be compromised in its
ability to control infection following administration of Schu
S4DpurMCD. To assess the type of damage inflicted on the lung
after i.n. vaccination with Schu S4 DpurMCD, lung tissues from
individual representative uninfected mice or mice infected i.n. with
wild-type Schu S4 or the Schu S4 DpurMCD mutant were
examined 5 days post-infection. A representative image of the lung
from an uninfected animal is shown for comparison (Fig. 5A and
B). Lungs from mice infected i.n. with WT Schu S4 show
pronounced areas of hemorrhage in the airspaces at this timepoint
(Fig. 5C and D). In addition, there are large foci of necrosis
associated with bronchioles and arteries, with pockets of necrotic
cellular debris within bronchiolar airspaces involving approxi-
mately 35% of the lung tissue examined (Fig. 5C and D). Although
lungs from mice infected i.n. with a single dose of 10
6 CFUs of
Schu S4 DpurMCD (Fig. 5E and F) do not show the same extensive
regions of necrosis as seen in Schu S4-infected animals, multiple
small foci of acute inflammation can be observed along with areas
of neutrophil influx within the lung parenchyma affecting less than
20% of the total lung tissue. Though the acute foci of
inflammation are no longer evident following vaccination (10
4
CFUs) and boosting (10
6 CFUs) with Schu S4 DpurMCD in the
lungs of the three representative mice examined, there are areas of
Figure 3. Survival of mice vaccinated with Schu S4 DpurMCD and challenged i.n. with 500 CFUs of wild-type Schu S4. Mice (n=5) were
vaccinated i.d. (A) or i.n. (B) with 10-fold serial dilutions of Schu S4 DpurMCD ranging from 10 to 10
6 CFUs. 21 days post-vaccination, mice were
challenged i.n. with 500 CFUs of wild-type Schu S4. The survival of mice was then monitored for 14 days. Vaccination dose is listed in CFUs, and mean
time-to-death was calculated for each dose. Asterisks indicate vaccinating doses at which MTD was significant compared to unvaccinated mice
(*P,0.05, **P,0.001 by log-rank analysis).
doi:10.1371/journal.pone.0002487.g003
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hemmorhage and rare foci of mixed cellular infiltrates suggestive
of granuloma formation (Fig. 5G and H). This indicates potential
chronic disease pathology resulting from vaccination alone. Thus,
i.n. vaccination with Schu S4 DpurMCD induces foci of damage in
the lungs of mice which may be detrimental to production of
proper lung immunity in response to virulent SchuS4 challenge.
Discussion
F. tularensis is a highly infectious bacterium, with as few as ten
inhaled organisms able to cause severe disease in humans [2,4]. Its
extreme infectivity and capacity to cause debilitating and possibly
fatal illness has warranted its classification by the United States
Centers for Disease Control and Prevention as one of six Category
A Select Agents most likely to be used as a biological weapon. In
light of recent bioterrorism concerns, the lack of a licensed vaccine
has prompted a renewed interest in generating a vaccine able to
protect against infection with highly virulent F. tularensis biotypes.
In this study, the utility of an unmarked Schu S4 deletion mutant
as a live vaccine candidate was assessed. The purMCD locus encodes
three enzymes (phosphoribosylaminoimidazol synthetase, SAICAR
synthetase, and phosphoribosylamine-glycine ligase) required for the
de novo synthesis of purine nucleotides. Deletion of these genes
abrogates the ability of F. tularensis Schu S4 to replicate in human
macrophages and epithelial cells in vitro. Though unable to persist in
host cells in vitro, purMCD mutants of F. tularensis remain able to
escape from the host cell phagosome prior to fusion with the
lysosome, where they persist in the host cytosol before being cleared
[16].Theabilitytoescapefromthephagosomemaybeanimportant
consideration in developing a live attenuated vaccine for Francisella.
Mutants unable to escape from the phagosome, such as those
defective for IglC production, are attenuated for virulence, but fail to
confer protective immunity against virulent F. tularensis challenge
[12]. While the exactreasons for this are unclear, escape of Francisella
into the cytosol is important for activation of host innate immune
recognition systems, particularly the inflammasome, which is known
to be crucial to host defenses against intracellular pathogens [22].
Phagosomal escape has also been shown to be important for
processing and release of IL1-b, a cytokine that plays a key role in
initiating and maintaining the pro-inflammatory response necessary
for Francisella immunity [23]. In addition, phagosome escape and
Table 2. Vaccination and Challenge results.
Row Vacc. +/2 Boost Challenge Intradermal Intranasal
Survival MTD (days)
a Survival MTD (days)
a
1 LVS (200 CFU) 2 Schu S4 (100 CFU) 3/3 .21.0 3/3 .21.0
2 2 Schu S4 (2000 CFU) 3/3 .21.0 0/3 7.0
3 2 NR-648 (150 CFU) 3/3 .21.0 1/3 15.0
4 2 NR-648 (3000 CFU) 3/3 .21.0 1/3 15.0
5 + Schu S4 (100 CFU) 3/3 .21.0 3/3 .21.0
6 + Schu S4 (2000 CFU) 3/3 .21.0 1/3 11.0
7 + NR-648 (150 CFU) 3/3 .21.0 3/3 .21.0
8 + NR-648 (3000 CFU) 3/3 .21.0 1/3 16.0
9L V S DpurMCD (10
6 CFU) 2 Schu S4 (100 CFU) 0/3 8.3 0/3 6.0
10 2 Schu S4 (2000 CFU) 0/3 7.3 0/3 5.0
11 2 NR-648 (150 CFU) 0/3 8.7 0/3 7.7
12 2 NR-648 (3000 CFU) 1/3 11.7 0/3 7.0
13 + Schu S4 (100 CFU) 3/3 .21.0 3/3 .21.0
14 + Schu S4 (2000 CFU) 3/3 .21.0 1/3 16.7
15 + NR-648 (150 CFU) 3/3 .21.0 3/3 .21.0
16 + NR-648 (3000 CFU) 3/3 .21.0 2/3 19.0
17 Schu S4 DpurMCD (10
4 CFU) 2 Schu S4 (100 CFU) 2/3 16.3 1/7 10.7
18 2 Schu S4 (2000 CFU) 3/3 .21.0 0/3 6.3
19 2 NR-648 (150 CFU) 2/3 16.3 0/3 9.0
20 2 NR-648 (3000 CFU) 3/3 .21.0 2/3 16.3
21 + Schu S4 (100 CFU) 3/3 .21.0 5/7 18.0
22 + Schu S4 (2000 CFU) 3/3 .21.0 0/3 6.7
23 + NR-648 (150 CFU) 3/3 .21.0 3/3 .21.0
24 + NR-648 (3000 CFU) 2/3 16.7 2/3 18.0
25 None Schu S4 (100 CFU) 0/3 6.7 0/3 5.0
26 Schu S4 (2000 CFU) 0/3 5.7 0/3 5.0
27 NR-648 (150 CFU) 0/3 6.7 0/3 7.0
28 NR-648 (3000 CFU) 0/3 6.3 0/3 6.3
aMTD, mean time-to-death was calculated for a 21-day period.
doi:10.1371/journal.pone.0002487.t002
DpurMCD Mutants of Schu S4
PLoS ONE | www.plosone.org 6 June 2008 | Volume 3 | Issue 6 | e2487bacterial persistence in the cytosol is likely to be important for MHC
Class I presentation of important antigens [24]. The inability of the
Schu S4 DpurMCD to replicate in vitro also correlates to a significant
reduction in virulence in vivo. The LD50 values for these strains are
$10
6-fold higherthanthatseen with the wild-typeorcomplemented
mutant derivatives which have an observed LD50,10 CFUs.
A growing body of evidence indicates that the ideal live
attenuated Francisella vaccine should be amenable to delivery by
the respiratory route to promote optimal protective immunity
against virulent type A F. tularensis delivered aerogenically
[10,11,25]. While i.d. vaccination with high doses of Schu S4
DpurMCD enhances the MTD of animals challenged i.n. with type
A F. tularensis, all i.d. vaccinated animals eventually succumb to
infection following challenge. This is likely a result of the limited
dissemination of the Schu S4 DpurMCD mutant to the lung
following vaccination via this route. I.n. vaccination of mice with
Schu S4 DpurMCD is capable of providing protection against
subsequent i.d. challenge with virulent type A and type B F.
tularensis; however, protection against these strains remains limited
when the challenge strains are delivered by the i.n. route. The
extent of protection observed is similar to that seen following
vaccination with LVS or LVS DpurMCD. Though able to partially
limit the dissemination and/or survival of wild-type Schu S4 in the
liver and spleen, i.n. vaccination with Schu S4 DpurMCD fails to
appreciably limit growth of the challenge strain within the lungs.
One possible explanation for this is that administration of high
doses of Schu S4 DpurMCD i.n. induces tissue damage in the lungs,
thus limiting the ability to subsequently clear large doses of the
challenge organism. Although Schu S4 DpurMCD is deleted for
components of the purine biosynthetic operon and is unable to
proliferate within the lungs, this strain is expected to otherwise
express all of the virulence determinants necessary for successful
infection. In addition, respiratory infection with virulent type A
strains is known to result in a robust pro-inflammatory response
within the lungs of mice [26]. Histological examination of lungs
from mice vaccinated with Schu S4 DpurMCD show multiple foci/
pockets of acute inflammation within the lung parenchyma and
associated airways, along with very small foci of necrosis. Thus,
inflammation resulting from challenge with wild-type Schu S4, in
addition to any loss of tissue integrity following vaccination with
Schu S4 DpurMCD, may limit the ability of these animals to
control infection in the lung. Regardless, studies are currently
underway to investigate alterations in lung architecture and the
immune response elicited following vaccination with Schu S4
DpurMCD, LVS DpurMCD, or wild-type LVS.
It has been widely speculated that the limitations of LVS as a
live vaccine strain may be countered by construction of an
attenuated type A derivative that carries a single or multiple
defined non-reverting mutations. In theory, this would account for
any antigenic differences between the two subspecies, and/or
differences in the cell types encountered during infection.
Comparison of the protective efficacy provided by the strains
utilized in this study indicates that Schu S4 DpurMCD offers no
better protection than LVS as a live vaccine. This suggests that the
inability of LVS to confer protection is not likely due to antigenic
variation between the subspecies. In addition, vaccinating and
boosting with LVS DpurMCD conferred protection at levels that
were comparable to that seen with wild-type LVS, suggesting that
deletion of the purMCD locus does not adversely affect expression
of important antigenic determinants. Given these observations,
and the retained ability of the Schu S4 DpurMCD mutant to
induce tissue damage in the lungs following i.n. vaccination even
in the absence of bacterial proliferation, we speculate that
introduction of the DpurMCD allele into an otherwise wild-type
strain from the less pathogenic type B biovar may result in an
attenuated derivative that could provide the necessary immuno-
genicity without the associated reactogenicity. Recent advances in
the area of F. tularensis genetics should allow for mutants to be
readily made in this genetic background. Regardless, further work
is still needed to characterize the protective response(s) elicited by
vaccination with attenuated mutants of type A or type B F.
tularensis, and define the antigenic determinants responsible for
stimulating this response.
Figure 4. Bacterial burden in mice vaccinated i.n. with Schu S4
DpurMCD and challenged with wild-type Schu S4. Mice were
unvaccinated, vaccinated (10
4 CFUs), or vaccinated (10
4 CFUs) and
boosted (10
6 CFUs) with Schu S4 DpurMCD. 42 days post-vaccination,
mice were challenged with 100 CFUs of wild-type Schu S4. All
vaccinations and challenges were administered by the i.n. route. At
one, three, and five days post-challenge, liver, spleen, and lungs from
infected animals were aseptically removed and homogenized, and a
standard plate count performed on MH containing Amp. The mean and
standard errors of CFUs from 3 animals per time point is shown.
Asterisks indicate a significantly reduced bacterial burden compared to
unvaccinated animals (P,0.001 by two-way ANOVA).
doi:10.1371/journal.pone.0002487.g004
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Bacterial strains and culture conditions
F. tularensis LVS was a gift from Karen Elkins. F. tularensis NR-
648 is a virulent type B strain and was a kind gift from Rick Lyons.
F. tularensis Schu S4 was obtained from BEI Resources. All work
with NR-648 or Schu S4 and its derivatives were conducted under
BSL3 or ABSL3 containment, and were approved by the
Institutional Biosafety Committees or Institutional Animal Use
and Care Committees of the Medical College of Wisconsin
(MCW) or The Ohio State University (OSU). MCW and OSU are
registered with the Centers for Disease Control and Prevention to
work with virulent strains of F. tularensis. F. tularensis strains were
grown aerobically at 37uC in modified Mueller-Hinton (MH)
broth or agar (Difco) supplemented with 1% proteose peptone,
2.5% fetal bovine serum (Invitrogen), 0.25% ferric pyrophosphate,
1% dextrose, and 2% IsoVitalex. When required, kanamycin
(10 mg/ml), ampicillin (50 mg/ml), or sucrose (10%) was added to
media. Bacterial inocula for animal infection studies was generated
by streaking F. tularensis strains onto MH plates, resuspending
bacteria in 16PBS, and diluting to the appropriate concentration.
All cloning was performed in Escherichia coli DH5a. E. coli was
Figure 5. Histopathology of lungs from mice infected with Schu S4 derivatives. Mice were infected i.n. with 16PBS (A, B), 100 CFUs of wild-
type Schu S4 (C, D), or 10
6 CFUs of Schu S4 DpurMCD (E, F). Infections were allowed to proceed for 5 days before animals were euthanized and lungs
removed for histology. A subset of animals was also vaccinated i.n. with 10
4 CFUs of Schu S4 DpurMCD and boosted i.n. 21 days later with 10
6 CFUs
Schu S4 DpurMCD. Animals were then administered 16PBS 42 days post-vaccination (21 days post-boost) and euthanized 4 days later for histological
analysis of lung tissues (G, H). Images were captured at 1006(A, C, E, G) or 4006(B, D, F, H) magnification. Representative arteries (a) and bronchioles
(b) are labeled. Examples of neutrophils are indicated by black arrowheads and necrosis by black arrows.
doi:10.1371/journal.pone.0002487.g005
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supplemented with 50 mg/ml kanamycin when required.
Allelic replacement and complementation
Unmarked deletion mutations were generated in F. tularensis
LVS and Schu S4 using a strategy similar to that described
previously [16]. Briefly, 1.0-kb regions flanking purMCD were
amplified from F. tularensis LVS and directionally cloned into
suicide plasmid pTZ699 [16]. A groE-aph kanamycin resistance
cassette was then cloned into the unique SmaI site present in the
backbone of pTZ699 to generate pTZ866. This plasmid was then
electroporated into wild-type F. tularensis LVS or Schu S4 and
transformants selected on MH containing kanamcin. Integration
of the plasmid into the homologous region on the F. tularensis
chromosome was confirmed by PCR. Merodiploids were then
spread or struck on MH medium containing 10% sucrose to
enrich for derivatives that had undergone a second recombination
event and resolved the plasmid containing the kanamycin
resistance determinant. Resulting clones were patched onto
Chamberlain’s defined medium (CDM) and MH containing
kanamycin to confirm auxotrophy and loss of antibiotic resistance,
respectively. Mutants were confirmed by PCR and by Southern
blot analysis. Complementation of the DpurMCD allele in both
LVS and Schu S4 was accomplished by introduction of pTZ752 as
described previously [16].
Isolation and infection of macrophages and lung
epithelial cells
Human peripheral blood monocyte-derived macrophages
(hMDMs) were isolated from buffy coats obtained from the
BloodCenter of Southeastern Wisconsin. Buffy coats were layered
onto Histopaque (Sigma) gradients to enrich for lymphocytes and
monocytes. Resulting pellets were washed twice with ice cold PBS
containing 0.05% BSA, suspended in RPMI 1640 (Gibco), and
monocytes further enriched by layering onto Percoll (GE
Healthcare) gradients. Resulting cells were suspended in RPMI
1640 complete medium containing 2 mM L-glutamine and 20%
human serum (Gemini Bioproducts), transferred into Teflon-
coated tissue culture cups (Savillex), and incubated for 5 days to
allow for differentiation of monocytes into macrophages. Macro-
phages were seeded into 12-well tissue culture plates at a density of
1610
5 cells per well and allowed to adhere overnight. Non-
adherent cells were removed by washing with RPMI 1640 prior to
infection with F. tularensis. Mouse peritoneal macrophages were
obtained by injecting mice intraperitoneally with 2 ml of 2%
thioglycolate (Sigma) and collecting peritoneal cells by lavage with
sterile phosphate-buffered saline after 3 days. Peritoneal macro-
phages were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum and 2 mM
L-glutamine. J774A.1 macrophages were maintained as previously
described [16]. A549 human lung epithelial cells (ATCC CCL-
185) were cultured in RPMI 1640 containing 5% fetal bovine
serum (FBS; HyClone) and 2 mM L-glutamine. 12-well tissue
culture plates were seeded at a density of 1610
5 for F. tularensis
infection. All cells were maintained at 37uC in humidified air
containing 5% CO2.
For infection of macrophages and A549 cells, F. tularensis strains
were grown to mid-exponential phase, diluted to the appropriate
concentration in pre-warmed RPMI or DMEM, respectively, and
added to cells at an MOI of 1 bacterium per cell. Cells were then
incubated for 2 h to allow bacterial internalization, washed with
PBS, and suspended in fresh medium containing 5 mg/ml
gentamicin for killing of extracellular bacteria. At specific times
following infection, infected cells were washed with PBS, lysed
with sterile water or 0.5% saponin (macrophages and A549 cells,
respectively), and the number of CFU determined by plating serial
10-fold dilutions on MH agar medium.
Mouse infection experiments
6- to 8-week-old female Balb/c mice (Harlan Sprague) were used
in all infection studies. Mice were anesthetized prior to infection by
intraperitoneal injection of 250 mg/Kg Avertin (Sigma), resulting
in approximately 30 min of surgical anesthesia. For intradermal
infections, mice were infected at the base of the tail with a 100 ml
inoculum. Alternatively, anesthetized mice were infected intrana-
sally with a 25 ml inoculum directly into the nares. The actual
number of bacteria delivered for each infection was quantified by
plating the initial inoculum on MH agar. For analysis of bacterial
burden in infected mice, mice were euthanized at specific times
after infection, and the lung, liver and spleen removed aseptically.
Infected tissues were homogenized and diluted in PBS, and total
CFU determined by plating on MH agar medium containing Amp.
LD50 experiments were conducted essentially as described [16].
For vaccination-challenge studies, groups of mice were inoculated
i.n. with 16 PBS, or vaccinated with defined doses of wild-type
LVS, the Schu S4 DpurMCD mutant, or the LVS DpurMCD
mutant. Some animals in each group received a booster
immunization of the same strain given 21 days post-vaccination.
42 days after the initial vaccination, mice were challenged i.n. with
moderate or high doses of wild-type Schu S4 or NR-648. All
infections were allowed to proceed to the designated times or until
animals become visibly moribund. Mean time-to-death was
calculated by dividing the sum of the survival times of all mice by
the total number of mice examined, with surviving animals given a
time of 21 days, when the experiment was terminated.
Histopathology
Histology was conducted on lungs from representative mice
infected with various F. tularensis derivatives. At various times
following vaccination and/or infection, lungs were removed
aseptically and fixed in 10% zinc formalin for a minimum of 24
hours. Lung tissues were then processed and embedded in
paraffin, and five-micrometer sections mounted on slides. Between
4 and 6 levels were obtained for each tissue block. Slides were
stained with hematoxylin/eosin, and examined by an anatomic
pathologist (N.H.S) using a Nikon E400 upright microscope.
Between 10–25 106fields were examined per tissue level. Images
were captured using a SPOT camera and SPOT software version
3.5.4 (Diagnostic Instruments, Inc., USA).
Statistical Analysis
A two-way ANOVA analysis was used to determine significance
in survival between F. tularensis derivatives in hMDM and A549
epithelial cells (Fig. 1). A test for trend of survival probabilities [21]
was applied to determine significance in survival probabilities
following i.d. or i.n. vaccination with Schu S4 DpurMCD and
challenge with wild-type Schu S4 (Fig. 3). Before application of this
test, log-rank or Wilcoxon weights were used to specify weight
functions. Log-rank analysis was applied to MTD values to
confirm significance relative to that seen in unvaccinated control
animals. A Cochran-Armitage trend analyses [27] was used to
confirm that a significant trend in survival probabilities existed
among vaccinated and unboosted, and vaccinated and boosted
groups relative to naı ¨ve mice in vaccination/challenge studies
(Table 2). A proportional hazards model (Cox model) was used to
model survival times, where vaccinating strains were compared for
boost effect and vaccine vs. control effect [21]. Finally, for analysis
of bacterial burdens in mice following Schu S4 challenge in
DpurMCD Mutants of Schu S4
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(Fig. 4), a log transformation with base ten was applied to the
data before analysis by two-way ANOVA. All values were
considered significant at P,0.05, and highly significant at
P,0.001. Methodological limitations included small sample sizes
limiting the power of the tests, and reliability of the effect
estimation (hazard ratio+regression coefficients).
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